Adimmune Corp - Asset Resilience Ratio
Adimmune Corp (4142) has an Asset Resilience Ratio of 0.54% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 4142 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Adimmune Corp's Asset Resilience Ratio has changed over time. See how leveraged is Adimmune Corp's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Adimmune Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Adimmune Corp (4142) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$45.51 Million | 0.54% |
| Total Liquid Assets | NT$45.51 Million | 0.54% |
Asset Resilience Insights
- Limited Liquidity: Adimmune Corp maintains only 0.54% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Adimmune Corp Industry Peers by Asset Resilience Ratio
Compare Adimmune Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Adimmune Corp (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Adimmune Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.50% | NT$127.51 Million ≈ $4.02 Million |
NT$8.48 Billion ≈ $267.21 Million |
+1.21pp |
| 2023-12-31 | 0.29% | NT$27.51 Million ≈ $866.62K |
NT$9.48 Billion ≈ $298.81 Million |
-0.97pp |
| 2022-12-31 | 1.26% | NT$115.51 Million ≈ $3.64 Million |
NT$9.15 Billion ≈ $288.23 Million |
-1.72pp |
| 2021-12-31 | 2.98% | NT$239.00 Million ≈ $7.53 Million |
NT$8.01 Billion ≈ $252.36 Million |
-1.14pp |
| 2020-12-31 | 4.13% | NT$349.56 Million ≈ $11.01 Million |
NT$8.47 Billion ≈ $266.96 Million |
+3.34pp |
| 2019-12-31 | 0.79% | NT$51.82 Million ≈ $1.63 Million |
NT$6.57 Billion ≈ $207.00 Million |
+0.28pp |
| 2018-12-31 | 0.51% | NT$29.12 Million ≈ $917.60K |
NT$5.68 Billion ≈ $178.90 Million |
+0.51pp |
| 2017-12-31 | 0.00% | NT$150.00K ≈ $4.73K |
NT$5.75 Billion ≈ $181.03 Million |
-0.05pp |
| 2016-12-31 | 0.06% | NT$3.75 Million ≈ $118.15K |
NT$6.78 Billion ≈ $213.76 Million |
+0.48pp |
| 2015-12-31 | -0.43% | NT$-23.25 Million ≈ $-732.57K |
NT$5.43 Billion ≈ $171.22 Million |
-0.03pp |
| 2014-12-31 | -0.40% | NT$-23.25 Million ≈ $-732.57K |
NT$5.86 Billion ≈ $184.53 Million |
+0.03pp |
| 2013-12-31 | -0.42% | NT$-23.25 Million ≈ $-732.57K |
NT$5.49 Billion ≈ $172.85 Million |
-0.95pp |
| 2012-12-31 | 0.53% | NT$31.52 Million ≈ $992.93K |
NT$5.99 Billion ≈ $188.83 Million |
+0.09pp |
| 2011-12-31 | 0.44% | NT$24.43 Million ≈ $769.81K |
NT$5.61 Billion ≈ $176.69 Million |
-0.64pp |
| 2010-12-31 | 1.08% | NT$58.47 Million ≈ $1.84 Million |
NT$5.42 Billion ≈ $170.67 Million |
-0.29pp |
| 2009-12-31 | 1.37% | NT$78.17 Million ≈ $2.46 Million |
NT$5.71 Billion ≈ $179.85 Million |
-11.52pp |
| 2008-12-31 | 12.89% | NT$540.57 Million ≈ $17.03 Million |
NT$4.19 Billion ≈ $132.11 Million |
+12.58pp |
| 2007-12-31 | 0.31% | NT$6.65 Million ≈ $209.61K |
NT$2.14 Billion ≈ $67.53 Million |
-- |
About Adimmune Corp
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops Adim… Read more